SOMA (carisoprodol) by Viatris is identified. First approved in 1959.
Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
SOMA (carisoprodol) is an oral muscle relaxant approved in 1959 for acute musculoskeletal pain and spasticity. It works by modulating interneuronal activity in the spinal cord and descending reticular formation, reducing muscle tension without direct action on skeletal muscle. Carisoprodol is a small-molecule CNS depressant used as an adjunct to rest and physical therapy.
As LOE approaches, the brand team is likely consolidating and shifting focus toward competitive positioning and retention of remaining market share in a crowded muscle relaxant category.
identified. In animal studies, muscle relaxation induced by carisoprodol is associated with altered interneuronal activity in the spinal cord and in the descending reticular formation of the brain.
Muscle Relaxant
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Long-Term Safety and Tolerability of Nizubaglustat in Participants With Rare Lysosomal Disorders
Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine Neoplasms
Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Navepegritide and Lonapegsomatropin in Achondroplasia
Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)
Impact of Gender-Transformative Interventions on Contraceptive Use and Reproductive Autonomy in Somalia
Worked on SOMA at Viatris? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moViatris is hiring 2 roles related to this product
SOMA represents a defensible but declining career opportunity in a mature, commoditized market with limited growth prospects. Professionals on this product team are primarily focused on market retention, cost management, and competitive pricing rather than innovation or expansion—better suited for those seeking stability over high-growth roles.